Fol. Biol. 2003, 49, 217-222
https://doi.org/10.14712/fb2003049060217
Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors
Individual author index pages
Other articles of these authors
-
Genetically Modified Vaccines Augment the Efficacy of Cancer Surgery and Chemotherapy
J. Bubeník
2009, Vol. 55, Issue 6, pp. 199-200 -
Characteristics of Two Mouse bcr-abl-Transformed Cell Lines. II. Pathological Lesions Induced in Mice
František Jelínek, E. Sobotková, V. Vonka
2005, Vol. 51, Issue 4, pp. 93-102 -
Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells
Jana Šímová, J. Bubeník, J. Bieblová, M. Indrová, T. Jandlová
2005, Vol. 51, Issue 1, pp. 19-24 -
Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects
Marie Indrová, M. Reiniš, J. Bubeník, T. Jandlová, J. Bieblová, V. Vonka, J. Velek
2004, Vol. 50, Issue 6, pp. 184-193 -
The Role of NK1.1+ Cells in the Protection against MHC Class I+ HPV16-Associated Tumours
Jana Šímová, J. Bubeník, J. Bieblová, T. Jandlová
2004, Vol. 50, Issue 6, pp. 200-202 -
MHC Class I+ and Class I- HPV16-Associated Tumours Expressing the E7 Oncoprotein Do Not Cross-react in Immunization/Challenge Experiments
Jana Šímová, R. Mikyšková, V. Vonka, J. Bieblová, J. Bubeník, T. Jandlová
2003, Vol. 49, Issue 6, pp. 230-234 -
Immunotherapy of HPV 16-Associated Tumours with Tumour Cell Line/Dendritic Cell Line (TC-1/DC2.4) Hybrid Vaccines
Jana Šímová, J. Bieblová, T. Jandlová, J. Bubeník
2003, Vol. 49, Issue 5, pp. 203-206
